Electrophilic Natural Products as Covalent Drug Leads Through Reactivity Control, Target Selectivity, Proteome Engagement, and Medicinal Chemistry Optimization

Download PDF

Electrophilic natural products are often interpreted through an unhelpful binary: their reactive groups are either treated as liabilities to be removed or as privileged motifs that confer covalent pharmacology. Neither position adequately reflects how covalent drugs are discovered or how natural electrophiles behave in biological systems. This conceptual framework examines electrophilic natural products as candidate covalent leads by separating intrinsic chemical reactivity from molecular recognition, target-site engagement, kinetic behavior, proteome selectivity, functional pharmacology, and developability. Warhead identity alone cannot determine whether covalency will be productive, selective, reversible, durable, or toxic. Natural electrophiles instead occupy a continuum in which scaffold architecture, electronic activation, local protein environment, exposure, and time jointly influence observed reactivity. Building on these distinctions, the article develops a proposed Reactivity–Recognition–Engagement framework for lead selection and positions chemoproteomic evidence as a critical gate between plausible covalent binding and credible proteome-level selectivity. Medicinal chemistry is treated not as a process of eliminating electrophilicity, but of tuning warhead reactivity, recognition geometry, and exposure so that target engagement is favored over uncontrolled chemical attack. The framework does not define validated thresholds, predict clinical safety, or establish universal advancement rules. Its purpose is to organize experimental evidence so that electrophilic natural products are neither rejected because they react nor advanced merely because they covalently bind. Electrophilicity is thereby reframed as a controllable pharmacological variable rather than a categorical lead-selection verdict.